Clinical Trial Update: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating KN046 plus lenvatinib in advanced non-small cell lung cancer after failure of anti-PD-(L)1 therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KN046
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: TERMINATED